MedTrace Logo

Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy

NCT03513172 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2018-05-01

No results posted yet for this study

Summary

In this study, investigators will be examining the intraocular pressure lowering effect of brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.

Conditions

  • Post-Injection Intraocular Pressure Spikes

Interventions

DRUG

topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)

The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.

Sponsors & Collaborators

  • Dr. Efrem Mandelcorn

    collaborator UNKNOWN

  • University of Toronto

    lead OTHER

Principal Investigators

  • Efrem Mandelcorn, MD, FRCSC · University Health Network, Toronto

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-15
Primary Completion
2017-07-15
Completion
2017-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03513172 on ClinicalTrials.gov